MRC - Manufacturers Resource Center

 

Orasure Technologies Receives Three Emergency Use Authorizations

 

Orasure Technologies Receives Three Emergency Use Authorizations for Its COVID -19 Rapid Antigen Tests

Orasure Press Release
June 7, 2021 at 9:18 AM EDT

Branded as InteliSwab™, the easy-to-use diagnostic tests rapidly detect active COVID-19 infection

BETHLEHEM, Pa., June 07, 2021 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its COVID-19 rapid antigen tests, which the Company is branding as InteliSwab™. These tests detect active COVID-19 infection. The FDA has authorized the InteliSwab™ COVID-19 Rapid Test for Over-the-Counter (OTC) use without a prescription. FDA has also authorized the InteliSwab COVID-19 Rapid Test Pro for professional use in point of care (POC) CLIA-waived settings, and the InteliSwab COVID-19 Rapid Test Rx for Prescription Home Use. Read […more]

Download PDF